Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm adagrasib trial in KRAS G12C-mutant NSCLC including elderly or ECOG 2 patients
2022-002736-31Phase 2Active
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Nov 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adagrasib in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Objective response rate. Started Nov 2022; status: active.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-002736-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002736-31.